Scholarship and Drug Discovery at Novartis

"In the academic circles from where I came, Novartis has a reputation for cultivating the brightest minds in biomedicine in pursuit of the highest hanging fruit," writes Jay Bradner.

(Originally published Dec. 6 on LinkedIn)

Today we learned that Novartis is among the top three companies in the world for high-quality science, notably topping the list of collaborative institutions in Nature Index's Science 2017.

Jay Bradner is president at the Novartis Institutes for BioMedical Research

Published for the first time in this format, the Index ranks the scholarship of the leading 100 companies across all industries over the past five years (2012-2016). Further, the analysis ranks industry-academic partnerships for high-quality research. Research performance is benchmarked through contributions to highly selective peer reviewed journals.

I can't say that I am surprised, but I must say that I am delighted. In the academic circles from where I came, Novartis has a reputation for cultivating the brightest minds in biomedicine in pursuit of the highest hanging fruit. Importantly, Novartis has a culture of scholarship en route to definitive drug discovery – sharing research early research reagents (chemical tools), publishing enabling datasets (e.g. Project Drive), and working shoulder-to-shoulder with innovators throughout academia.

Here are some highlights of the Nature Index:

  • Novartis contributions to science ranked #3 in the world across industries.
  • In total seven Novartis academic collaborations feature in the top 100 collaborations globally; the University of Basel (#1), Harvard University (#3), Swiss Federal Institute of Technology (#45), University of California, San Diego (#83) University of California San Francisco (#88), Stanford University (#90), Ludwig Maximilian University of Munich (#95).
  • With a total of 399, Novartis is also recognized for having the 7th most academic collaborations across all industries in the study.
  • In the pharmaceutical industry, Novartis contributed the most articles in the selective journals tracked by the index over the past 5 years.

I am so proud to see the intrinsic spirit of our science quantified so powerfully. Novartis truly is an elite scientific institution uniquely poised to contribute first fundamental insights into the natural world, and most importantly definitive medicines for life-threatening diseases.

To our associates, congratulations on this recognition of our tradition of open and collaborative science. To our collaborators, thank you for your shared belief in our ideas.

Please find the complete rankings and methodology employed for the index here.

Learn about career opportunities at Novartis

Novartis Survey Uncovers Real-World Impact of Immune Thrombocytopenia or ITP, a Rare Blood Disease, on Patients' Quality of Life

Findings from more than 1,300 patients across 13 countries showed ITP had especially high impact for many patients on emotional well-being (36%) and ability to work (28%).

Originally Published by Novartis.

Many patients with the rare blood disorder immune thrombocytopenia (ITP) find the disease has a negative impact on their everyday quality of life, according to interim results of a Novartis survey, called I-WISh, presented today at the 23rd Congress of the European Hematology Association (EHA) in Stockholm, Sweden (Abstract #PF654).

Read More Show Less

Open Resources at Novartis Help Drive Innovation

With external help from Novartis, an Argentinian researcher was able to begin his search for a new medicine for tuberculosis.

Originally Published by Novartis.

By K.E.D. Coan

"Back in Argentina, you never think of going for a real drug, but coming to Novartis completely changed what I thought was possible," says Bernardo Bazet Lyonnet, a postdoctoral researcher who first came to Novartis in 2016 as a Next Generation Scientist ( NGS). This program invites talented scientists from around the world for a bi-directional learning exchange at the Novartis campus in Basel, Switzerland.

Read More Show Less

Abbott Introduces the Afinion™ 2 Analyzer Rapid Test System for Diabetes Management

State-of-the-art multi-assay test system helps people with diabetes get the HbA1c results they need within three minutes — allowing more time for consultation and care during a single healthcare visit.

Originally Published by Abbott.

Abbott announced the launch of its Afinion™ 2 analyzer in the U.S., the newest generation of the Afinion test system. The Afinion 2 builds on Abbott's heritage in diabetes care by empowering patients with information about their health that they can discuss with their providers during a single visit.

Read More Show Less

Third Novartis Phase III trial shows Kisqali combination therapy significantly improves PFS in HR+/HER2- advanced breast cancer

"In the advanced breast cancer setting, it is important to ensure we provide patients with treatment options that increase time to disease progression while also maintaining quality of life."

Originally Published by Novartis.

Novartis announced positive results from the third Phase III trial of Kisqali® (ribociclib) in advanced or metastatic breast cancer. MONALEESA-3 showed Kisqali plus fulvestrant significantly prolonged progression-free survival (PFS) compared to fulvestrant alone in postmenopausal women with hormone-receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced breast cancer. MONALEESA-3 is the largest phase III trial to evaluate efficacy and safety of a CDK4/6 inhibitor plus fulvestrant in multiple advanced breast cancer patient populations - first-line and second-line settings[1]. These data will be presented as an oral presentation at the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago (Abstract #1000) and published simultaneously in the Journal of Clinical Oncology.

Read More Show Less